Navigation Links
Hepatitis in Medical Technology

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... of direct-acting antivirals for the treatment of hepatitis C." The company plans to report the ... focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, ... programs or commercialization activities in hepatitis C, or any potential pipeline candidates, ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... received a vaccine. Reactivation of hepatitis B virus has been reported in patients who are ... if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as: feel ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... received a vaccine. Reactivation of hepatitis B virus has been reported in patients who are ... if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as: feel ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 ... studies address longstanding questions in the hepatitis C research community and provide important ... are constantly looking for ways to improve hepatitis C treatment outcomes by increasing response rates ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... potency in reducing viral load in patients with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and ... of patients chronically infected with the hepatitis C virus (HCV)(1). The study combined two oral ... "These are exciting times in our fight against hepatitis C, and the investigation of the innovative oral ...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

... in the treatment of patients with chronic hepatitis C. The Phase 3 results were the subject of two ... could become a leading treatment for chronic hepatitis C." The Phase 3 studies, known as ACHIEVE 1 ... of interferon-naive patients with chronic hepatitis C. ACHIEVE 1 was conducted in patients infected ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate the dose and ... needs of a growing population of patients with hepatitis C," said Rob Mitchell, Global Head of Roche's ... being held in Copenhagen, Denmark. About hepatitis C ...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

... (ribavirin) for 14 days of treatment in hepatitis C virus (HCV) treatment-naive patients infected ... rates in patients chronically infected with the hepatitis C virus." Viral Kinetic Performance ... idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology ...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... in which patients chronically infected with the hepatitis C virus (HCV) were treated for three days. The ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with ... in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the ... 1 is the most common and hardest to treat form of hepatitis C. In Part I of the study, a 48-week ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

... studies of clevudine for the treatment of chronic hepatitis B (HBV) infection. Pharmasset recently ... receiving clevudine as prescribed therapy for hepatitis B in South Korea. Though only a small number of ... adefovir for 96 weeks in patients with chronic hepatitis due to infection with e-antigen ...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

... nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with ... the United States failed prior treatment of their hepatitis C virus (HCV) infection, representing a large and ... therapies to meet the needs of patients with hepatitis C." Data from the clinical study supporting ...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon ... treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008). Albinterferon alfa-2b is being ... become a market-leading treatment for chronic hepatitis C." Stefan Zeuzem, M.D., Professor of ...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

... first Phase 3 results for Albuferon in chronic hepatitis C, and the data were positive. We will have ... for First of Two Phase 3 Trials in Chronic hepatitis C Patients; Results of Second Phase 3 Trial ... patients with genotypes 2 and 3 chronic hepatitis C. The data showed that the rate of sustained ...

Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor

... announced today the advancement of their hepatitis C (HCV) collaboration with a first-in-human ... trial in healthy volunteers. About the hepatitis C Virus hepatitis C is a liver disease affecting more than 170 ...

Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... The study is evaluating IDX184 in treatment-naive hepatitis C genotype-1 infected patients. "We are ... with the progress that we have made in our hepatitis C discovery program in 2008, having successfully ... drugs from three major classes of direct-acting hepatitis C antivirals in clinical development." The ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... - Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for ... of Albuferon's first Phase 3 trial in chronic hepatitis C. We will have the results of Albuferon's ... in Phase 3 Trial in Genotypes 2 and 3 Chronic hepatitis C; Phase 3 Results in Genotype 1 Patients ...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

... activity in patients infected with chronic hepatitis C virus (HCV) in this first cohort of the study. ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... the potential of clevudine to treat hepatitis B (HBV), including its use in lamivudine ... Pharmasset made significant progress with our hepatitis C virus (HCV) programs. R7128, our lead HCV ... of oral therapeutics for the treatment of hepatitis B virus ...

Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis

... ), with password: h82a7q. Alcoholic hepatitis is a major cause of morbidity and mortality ... "The relationship between drinking and alcoholic hepatitis is complex. Not all heavy drinkers develop ... only moderately. Though damage from alcoholic hepatitis often can be reversed if patients stop drinking, ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 ... on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III ... protease inhibitor for treating chronic hepatitis C. The company also announced that it is ...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

... by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present ... Recommendations for Prevention and Control of hepatitis C Virus (HCV) Infection and HCV-Related Chronic ... the retreatment response in patients with chronic hepatitis C virus infection. Liver Int. 2007 ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with ... in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the ... 1 is the most common and hardest to treat form of hepatitis C," said Paul Kwo, M.D., associate professor ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... virological response (SVR) rates for hepatitis C patients as compared to regimens with another ... included all patients at our clinic who initiated hepatitis C treatment and met basic eligibility criteria," ... poor prognostic factors.(2)(3)(4)(5)(6) About hepatitis C ...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

... agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ... other agents approved or under investigation for hepatitis C. -- In a poster titled "Antiviral Efficacy of ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

... on precautionary measures. Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) ... During the clinical development program (n=3063), hepatitis has been reported in 0.5 percent of patients ... liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function ...

Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests

... evaluation, entitled "Laboratory Evaluation of hepatitis B Rapid Test for Use in Screening Walking Blood ... HBSAG test to use for screening blood donors for hepatitis B ("HBSAG") in the theater of war. The ... of the sensitivity of a test and means that hepatitis B infection can now be identified even with ...

Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications

... and the investment community." About hepatitis C hepatitis C is a blood-borne infectious disease of the ... 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost ...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

... of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ... (bid). ANA598 is the company's investigational hepatitis C non-nucleoside polymerase inhibitor. Phase I ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...

FDA Approves First Hepatitis B Viral Load Test

... HBV Test, the first assay for quantitating hepatitis B Virus DNA approved in the U.S. The test uses ... application of antiviral therapy along with the hepatitis B vaccine has helped reduce prevalence; however, hepatitis B remains a serious and potentially life ...

Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

... term follow up results from chronically infected hepatitis C patients strongly confirm and exceed positive ... long-term antiviral effect of therapeutic hepatitis C vaccination - Data pave the way and strongly ... clinical Phase II study targeting treatment-naive hepatitis C genotype-1 patients. As previously reported in ...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

... of clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.0 million increase ... Agency for Research on AIDS and Viral hepatitis (ANRS). Anticipated Highlights -- Announcing ... of oral therapeutics for the treatment of hepatitis B virus ...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

... patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of ... achieved undetectable HCV RNA levels. About hepatitis C hepatitis C is a blood-borne infectious disease of the ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... II study of boceprevir, its investigational oral hepatitis C protease inhibitor. The analysis showed a high ... study of 595 treatment-nave patients with chronic hepatitis C virus (HCV) genotype 1. In a 48-week ... search term boceprevir. About hepatitis C ...

Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

... inhibitor for the treatment of chronic hepatitis C. Today, Idenix also announced that is has ... are pleased with the progress we have made in our hepatitis C discovery program in the past few months," said ... of direct-acting antivirals for the treatment of hepatitis C." IDX184 Nucleotide Prodrug Polymerase ...

The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer

... to increase globally, due to the prevalence of hepatitis B and C infections," said Jordi Bruix, ... the United States. (1,2) In addition, chronic hepatitis B (HBV) and C (HCV) viral infections are the ... of Medicine, Asian Liver Center, "FAQ About hepatitis B," February 2008. ...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

... Clevudine+Viread(R) in 150 patients with chronic hepatitis B PRINCETON, N.J., July 8 ... National Agency for Research on AIDS and Viral hepatitis (ANRS), with the support of Pharmasset, Inc. ... their combination, for the treatment of chronic hepatitis B virus (HBV) infection in non-cirrhotic ....

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... (TLR7) mechanism for the treatment of chronic hepatitis C. Based on preclinical pharmacology testing and ... efforts in HCV. As an approach to treat hepatitis C, the TLR7 mechanism is independent from, and ... for 2008, Dr. Worland added, "Because the ANA773 hepatitis C program is highly leveraged off our oncology ...
Other Contents
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... of native animal species for food or commercial food ... factor in the decline of many species of primates ... that more than half of the species being consumed ... "By surveying not only the meat made available for ... the forest by hunters and brought to villages for ...
(Date:7/24/2014)... of 3.5 billion years of evolutionary trial and error, ... it may be reaching a tipping point. , In ... data published in Science , an international team ... animals is contributing to what appears to be the ... event. , Since 1500, more than 320 terrestrial vertebrates ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
(Date:7/25/2014)... July 26, 2014 2014 Deep ... Confocal Microscope Industry” is a professional and ... Confocal Microscope market. The report provides basic ... Scanning Confocal Microscope definition, classification, application, and ... This research covers international market analysis, including China’s ...
(Date:7/25/2014)... As reported by the Statesman Journal in the ... (7/20), police in Salem, MA as well as several other ... heroin epidemic that has taken many lives during the past ... case in which police were able to make two arrests ... pretending to be the victim and claiming to want to ...
(Date:7/25/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... Heather M. Young, PhD, RN, FAAN, of the ... of the Doris Schwartz Gerontological Nursing Research Award. ... Sciences Section, is given to a member of ... contribution to gerontological nursing research. , The award ...
(Date:7/25/2014)... July 25, 2014 Florida Hospital and MOSI ... not-for-profit organizations for years to come and make a difference ... a $2 million dollar check to provide the support needed ... will enable MOSI to transform the IMAX Dome Theatre from ... has the only IMAX Dome Theatre in the state of ...
(Date:7/25/2014)... Art of Facial Surgery has recently stepped ... Toronto who are looking for minor touch-ups to make them ... the American Academy of Facial Plastic and Reconstructive Surgery ... plastic surgery showed a surprising increase between 2012 and 2013. ... hair transplants increased by 7 percent and eyelid surgery increased ...
Breaking Medicine News(10 mins):Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3
Other TagsOther Tags